Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3644407 | 0.91 | LMNA (0.48) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL3647493 | 0.82 | LMNA (0.52) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL3648551 | 0.81 | LMNA (0.51) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL3645325 | 0.80 | LMNA (0.50) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL3646495 | 0.77 | LMNA (0.50) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL3650273 | 0.77 | LMNA (0.49) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL27955453 | 0.75 | LMNA (0.49) | MAPTLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL7890028 | 0.75 | POLB (0.49) | LMNAKMT2AMEN1POLB | |
| SCHEMBL7893776 | 0.75 | POLB (0.49) | LMNAKMT2AMEN1POLB | |
| SCHEMBL3648783 | 0.74 | LMNA (0.51) | MAPTLMNASMN1; SMN2TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188266-B1 | Novel piperazine amide derivatives | HOFFMANN LA ROCHE (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8288541-B2 | Piperazine amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| CN-101778831-A | Novel piperazine amide derivatives | HOFFMANN LA ROCHE | 2010-07-14 | — | — | CN | disclosed |
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | NR1H2, NR1H3, NR1I2 | MAPT 4226/4885LMNA 2374/4885SMN1; SMN2 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.